Adcendo Aps News Today

Data demonstrate that uPARAP is highly expressed in tumor samples obtained from glioblastoma multiforme patientsuPARAP targeting ADC shows cytotoxicity in glioblastoma multiforme cancer cells in vitro and exhibits potent in vivo anti-tumor activity in a glioblastoma multiforme PDX modelData provides evidence that uP...

/PRNewswire/ -- Adcendo ApS ("Adcendo"), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of...

Copenhagen-based biotech startup Adcendo ApS has collected an additional €31M in a Series A round led by Pontifax Venture Capital and existing investors Novo

Portfolio company Adcendo Aps, today announces extension of Series A financing to 82M EUR.BII publishes its 2022 Impact Report outlining the success of its portfolio companies in the past year.BII's

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

/PRNewswire/ -- Duality Biologics ("Duality"), a clinical-stage biotech company focused on discovering and developing a pipeline of antibody-drug conjugates...

The relative newcomer to the field, ripretinib, was compared to standard second-line treatment with sunitinib in patients with advanced gastrointestinal stromal tumors.

/PRNewswire/ -- Adcendo ApS ("Adcendo"), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of...

/PRNewswire/ -- Adcendo ApS ("Adcendo"), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of...